Abbreviated

Inclusion Criteria:

- PHASE I: 1st, 2nd or 3rd recurrence of: glioblastoma multiforme; gliosarcoma;
anaplastic astrocytoma; anaplastic mixed glioma; or anaplastic oligodendroglioma

- PHASE II: 1st recurrence of glioblastoma multiforme (only)

- Progressing/recurrent lesion which is ≥1cmx1cm. For the Phase II study the lesion
must be ≤5cmx5cm, defined by MRI only

- Be fully recovered from any prior therapy

- Have been treated at the time of original diagnosis by surgery and external beam
radiation to a dose of at least 5000 cGy; radiotherapy completed at least 6 weeks
before REOLYSIN® therapy

- Any intracranial surgery, except for stereotactic needle biopsy, must have occurred
at least 4 weeks before REOLYSIN® therapy

- Any anti-cancer drug therapy must have been completed at least 4 weeks (6 weeks in
the case of prior nitrosourea therapy) before REOLYSIN® therapy

- Have a life expectancy of ≥8 weeks and a Karnofsky Performance Status (KPS) of ≥60

- Absolute neutrophils ≥1.5 x10^9/L; hemoglobin ≥100g/L; platelets ≥100 x 10^9/L

- ALT ≥1.5 x ULN; total bilirubin ≥1.5 x ULN

- Serum creatinine ≤1.5 x ULN

- EKG with no evidence of active, acute cardiovascular disease

- PT within normal limit

- Women of childbearing potential must have a negative pregnancy test

- Reside or have suitable living arrangements within a reasonable geographical area of
the study site and be able to participate in all follow-up visits

- Patients requiring corticosteroids must be on a stable dose of steroid for at least
two weeks prior to baseline MRI and when entered in the study. Maximum daily dose of
24 mg/day of dexamethasone/decadron or equivalent

Abbreviated Exclusion Criteria:

- Patients who are sexually active and not willing to use barrier methods of
contraception; women who are breastfeeding

- Patients with unstable or serious concurrent medical or psychiatric conditions that
would interfere with study treatment or follow-up

- Patients with more than one discrete enhancing lesion on MRI, or radiographic
evidence of satellite lesions or leptomeningeal disease not obviously contiguous by
FLAIR imaging

- Patients who may require further neurosurgery within 4 weeks after REOLYSIN®
treatment

- Patients with a prior history of encephalitis, multiple sclerosis or other
significant chronic CNS disease

- Patients who have evidence of a current CNS infection, meningeal gliomatosis or
gliomatosis cerebri

- Patients with tumor that to be treated would require needle or catheter passage
through a ventricle, the posterior fossa or basal ganglia; or patients with tumors
invading the ventricle

- Patients who have previously participated in experimental viral therapy protocols

- Patients who have had prior intratumoral gene therapy or other intratumoral therapies

- Patients who have had Gliadel wafer therapy less than 6 months prior to enrollment

- Patients who have a history of bleeding disorders including congenital or acquired
coagulopathies

- Patients who have a known history of hepatitis or tuberculosis

- Patients who have a known history of hereditary or acquired immunodeficiency
including HIV infection

- Patients who have impaired non-neurological organ function (>Grade 1)

- Patients who have used systemic antiviral (or potentially antiviral) therapies within
28 days of enrollment

- Patients who have had brachytherapy or radiosurgery to the brain at any time

- Patients with previous or concurrent malignancies at other sites (except
surgically-cured carcinoma in situ of the cervix and non-melanoma skin cancer)

- Prior or current medical history indicating that a patient may be significantly
immunosuppressed